We hope to collect and include HCC patients receiving ICI treatment in future research and further verify the influence of DDR molecular type (DDR 1 and DDR2) and the DDR score on the outcomes of HCC patients receiving immunotherapy. This evidence concerns the gene DDR1 and hepatocellular carcinoma.